Moderna's mission to spearhead a revolution in vaccine R&D comes center stage today as the world faces a crucial turning point
Back in November, when the execs at Moderna laid plans for today’s day-long dive on their vaccine portfolio, the world of vaccine R&D was a much different place: dominated by slow-moving major players with thin margins that discouraged much by way of innovation. Without any public demands for a change.
Coronavirus changed all that — perhaps forever.
While Moderna’s years-long mission to create a new generation of vaccines — an early de-risking effort to highlight their broader chances — may be fundamentally intact, the public has become transfixed by the idea of a relatively near-term solution to a health crisis far beyond anything seen in living memory. And that is playing a major role in accelerating the work of a small group of vaccine revolutionaries that includes Moderna — even though they have yet to prove in a pivotal study that their technology is both safe and effective.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.